Is #ASCOhaiku a thing? You'd think if @aacr encouraged it at #aacr17 .... (I heard there might be a rivalry)
#asco17 @ASCO @ASCOPost
0
0
0
0
Hashtag
#AACR17
Advertisement · 728 × 90
Thanks to @ldtimmerman and @TimmermanReport for inviting me to contribute my reflections on #AACR17.
timmermanreport.com/2017/04/aacr-reflections...
0
0
0
0
So long #AACR17 - this was one for the books
0
0
0
0
Kudos to @AACR for giving a platform to so many #womeninSTEM at this #AACR17 meeting - inspiring stories and great science, it's a win-win
0
0
0
0
Segal simplifies lack of fitness in artificial system=p53 passenger mutation - don't agree with this #AACR17
0
0
0
0
Segal: high-susceptibility region in C-term of DBD domain of p53 - loss of function, as expected diff substitutions have diff effect #AACR17
0
0
0
0
Segal: mutants that retain WT p53 activity depleted from population as expected - so far all very predictable #AACR17
0
0
0
0
Finally Segar moves to p53 "mutome" - an analysis of 10,000 p53 mutants to look for the expected differences #AACR17
0
0
0
0
Q: colon - high cancer rates, small intestines low, but same exact mutation rates. More people bringing up complexities #AACR17
0
0
0
0
Interesting question on how does Peto's paradox factors into Tomasetti's model #AACR17
0
0
0
0
Willett: we cannot partition cancer risk into E,H&R - too much interplay between factors #AACR17
0
0
0
0
Q:how about H&E factors affecting polymerases?Tomasetti:stresses that even in perfect case scenario,polymerases still make errors #AACR17
0
0
0
0
Q: simplistic study, lack of correlation to risk, consider complexity, identify points of intervention for prevention at every stage #AACR17
0
0
0
0
Have you considered patterns of mutations?Tomasetti:he says upcoming work shows 37% lung cancer mutations due to R #AACR17
0
0
0
0
This seems to be biggest disconnect between what he says/it's perceived of this bad luck study #AACR17
0
0
0
0
Tomasetti stressing he's talking about mutations,not cancer cases.many people mentioned last sentence of his paper making connection #AACR17
0
0
1
0
Tomasetti q&a: we are not talking about cases in paper,only mutations, proportions of mutations #AACR17
0
0
0
0
Willett hints several times at complexity of issue, hinting at oversimplification-talking about effects that even diet has on risk #AACR17
0
0
0
0
I guess the point that Willett had is environmental factors likely downplayed in model, particularly combination of factors #AACR17
0
0
0
0
Crews on finding crevices on undraggable protein surfaces to PROTAC in order to target undraggable proteome #AACR17
0
0
1
0
PROTAC activity depends on integrity of ligand binding side, so shares some limitations of traditional small molecule drugs #AACR17
0
0
0
0
Crews: first orally active PROTAC anti-AR, now also anti-ERa, nice in vivo activity #AACR17
0
0
0
0
Crews: "linkerology" i.e. the science of optimizing links for "PROTACking" your protein of choice #AACR17
1
0
0
0
Crews: target validation with protein degradation using HALOProtacs - libraries of HALO-fusions available #tools #AACR17
0
0
0
0
Crews: introducing event-driven pharmacology, a term I will definitely adopt from today to discuss principles behind our approach #AACR17
0
0
0
0
D'Andrea: ezh2 inhibitor should not be combined w/parp inhibitor as it speeds up resistance -nice mouse data #AACR17
0
0
0
0
Grandis: patients very willing to participate to window trial - even if told that drugs are unlikely to benefit them #AACR17
0
0
0
0
Grandis: 5 ongoing HNC window trials for combinatorial treatments #AACR17
0
0
0
0
Grandis: window trials with checkpoint inhibitors maximizing amount of biological info that can be obtained from patients #AACR17
0
0
0
0
Hanahan: tumors are not bag of cells! Diverse and interact with surroundings #AACR17
0
0
0
0